Colorectal Cancer Coverage from Every Angle
Advertisement
Advertisement

Intravenous Analgesia and Postoperative Depression in Patients With Colorectal Cancer

By: Julia Fiederlein
Posted: Friday, September 4, 2020

Patient-controlled intravenous analgesia using dezocine in combination with sufentanil may relieve postoperative depression symptoms and improve sleep quality in patients with colorectal cancer, according to a recent double-blind trial published in PLOS One. However, Hong Li, MD, PhD, of the Army Medical University, Chongqing, China, and colleagues explained that the effects of dezocine when used alone remain unknown.

A total of 120 patients with colorectal cancer scheduled for elective laparoscopic resection between May 2018 and September 2018 were randomly assigned in a 1:1 ratio to receive either sufentanil with dezocine or sufentanil alone. After surgery, the Beck Depression Inventory and Beck Anxiety Inventory tests were administered, and sleep quality was subjectively assessed. Pain during rest, movement, and quality of recovery were evaluated on a numeric rating scale.

The investigators reported lower mean depression scores (7.3 vs. 9.9) in the experimental arm than in the control arm at 2 days after surgery (P < .001). The experimental arm also experienced a better night sleep quality on the day of surgery (P = .010) and 1 day after surgery (P < .001). Other outcomes did not appear to significantly differ between the arms.

“Postoperative analgesia using dezocine as a combination analgesic might be an optional analgesic strategy and should be recommended for patients with cancer,” the investigators concluded. “Further study is needed to validate these findings in greater detail and determine the effect of dezocine on the postoperative recovery of other cancer surgery patients.”

Disclosure: The study authors reported no conflicts of interest.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.
Advertisement
Advertisement